HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques

被引:96
作者
Ellis, CM
Dyson, MJ
Stephenson, TJ
Maltby, EL [1 ]
机构
[1] Shefield Childrens NHS Trust, Dept Cytogenet, Sheffield Genet Serv, Sheffield S10 2TH, S Yorkshire, England
[2] Royal Hallamshire Hosp, Dept Histopathol, Sheffield S10 2SF, S Yorkshire, England
关键词
D O I
10.1136/jcp.2004.023424
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: To compare the results of breast cancer sections with HercepTest(TM) immunohistochemistry (IHC) scores ranging from 0 to 3+ with fluorescence in situ hybridisation ( FISH) for HER2 amplification. The HER2 digital scoring application of the Micrometastasis Detection System (MDS(TM)) was used, together with manual scoring of FISH and HercepTest, to determine whether this system provides an accurate alternative. Methods: Paraffin wax embedded sections were stained using HercepTest and analysed by eye and automated quantitative image analysis. FISH was performed using the PathVysion(TM) fluorescent probe and scored by eye and automated quantitative image analysis using MDS. Results: Of 114 cases, 26% were amplified by FISH, whereas only 18% scored 3+; 32% of IHC 2+ cases were amplified by FISH, and one showed borderline amplification. Six percent of IHC negative cases ( 0 or 1+) were amplified by FISH, and one showed borderline amplification. Of IHC 3+ cases, 10% were non-amplified by FISH. Classification discrepancies were seen in 18% of HercepTest cases scored by eye and using the MDS system. MDS was consistent with visual FISH scoring and correctly differentiated most ambiguous visual IHC scores. Conclusions: FISH provides a more accurate and consistent scoring system for determining HER2 amplification than HercepTest. The MDS system provides a reliable, consistent alternative to visual IHC and FISH scoring. IHC is still a valuable technique to aid in identification of isolated or heterogeneous tumour populations for subsequent FISH analysis, and a combined FISH and HercepTest approach to all breast cancer cases may be the most efficient strategy.
引用
收藏
页码:710 / 714
页数:5
相关论文
共 16 条
[1]  
[Anonymous], 2001, Proc Am Soc Oncol
[2]   Evaluating HER2 amplification and overexpression in breast cancer [J].
Bartlett, JMS ;
Going, JJ ;
Mallon, EA ;
Watters, AD ;
Reeves, JR ;
Stanton, P ;
Richmond, J ;
Donald, B ;
Ferrier, R ;
Cooke, TG .
JOURNAL OF PATHOLOGY, 2001, 195 (04) :422-428
[3]   Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer [J].
Cianciulli, AM ;
Botti, C ;
Coletta, AM ;
Buglioni, S ;
Marzano, R ;
Benevolo, M ;
Cione, A ;
Mottolese, M .
CANCER GENETICS AND CYTOGENETICS, 2002, 133 (01) :66-71
[4]   HER-2 testing and trastuzurnab therapy for metastatic breast cancer: A cost-effectiveness analysis [J].
Elkin, EB ;
Weinstein, KC ;
Winer, EP ;
Kuntz, KM ;
Schnitt, SJ ;
Weeks, JC .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :854-863
[5]   Updated recommendations for HER2 testing in the UK [J].
Ellis, IO ;
Bartlett, J ;
Dowsett, M ;
Humphreys, S ;
Jasani, B ;
Miller, K ;
Pinder, SE ;
Rhodes, A ;
Walker, R .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (03) :233-237
[6]   Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization [J].
Hammock, L ;
Lewis, M ;
Phillips, C ;
Cohen, C .
HUMAN PATHOLOGY, 2003, 34 (10) :1043-1047
[7]   Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation [J].
Jones, FE ;
Stern, DF .
ONCOGENE, 1999, 18 (23) :3481-3490
[8]   Testing for HER2 in breast cancer [J].
Lewis, F ;
Jackson, P ;
Lane, S ;
Coast, G ;
Hanby, AM .
HISTOPATHOLOGY, 2004, 45 (03) :207-217
[9]  
MASS RD, 2000, P AN M AM SOC CLIN, V19, P75
[10]   C-ERBB-2 EXPRESSION AND RESPONSE TO ADJUVANT THERAPY IN WOMEN WITH NODE-POSITIVE EARLY BREAST-CANCER [J].
MUSS, HB ;
THOR, AD ;
BERRY, DA ;
KUTE, T ;
LIU, ET ;
KOERNER, F ;
CIRRINCIONE, CT ;
BUDMAN, DR ;
WOOD, WC ;
BARCOS, M ;
HENDERSON, IC .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (18) :1260-1266